News Category
Helus Pharma reports enrollment completion in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder, with topline data expected i...
Helus Pharma's appointment of veteran biopharma leader Michael Halstead as CEO signals strategic preparation for Phase 3 results and commercialization...
Ocumetics Technology Corp. has completed the second tranche of its private placement, raising $2.5 million to fund its first-in-human clinical trials ...
VERAXA Biotech shareholders approved proposals with over 99.94% support, enabling greater flexibility for growth through acquisitions, collaborations,...
VERAXA Biotech AG announced the advancement of its bispecific antibody-drug conjugate program VXA-222 following a key technical milestone in its colla...
Gerresheimer begins operations at a new state-of-the-art, sustainable plant in Zhenjiang Dagang, China, doubling its production capacity for glass pri...
The renaming of Darwin AG to Novogenia AG aligns the corporate identity with its core operating brand Novogenia GmbH, aiming to enhance market recogni...
NanoViricides reports progress on NV-387, an oral gummies antiviral candidate for the Bundibugyo ebolavirus outbreak in the DRC, with Phase II trial a...
Redwood AI Corp.'s inclusion in the CSE25 Index enhances its visibility among institutional and retail investors, reflecting its progress in AI-driven...
Helus Pharma announced fiscal 2026 financial results and progress on its Phase 3 trial for HLP003 in major depressive disorder, with topline data expe...
Quantum BioPharma Ltd. is featured in a BioMedWire editorial highlighting the urgent need for therapies that can repair myelin damage in multiple scle...
Nanomedicine and advanced drug-delivery systems are gaining traction as a cost-effective way to enhance existing oncology drugs, with Oncotelic Therap...
Quantum BioPharma is preparing to enter Phase 2 clinical trials for Lucid-MS, a first-in-class neuroprotective drug candidate that directly targets my...
VERAXA Biotech announced new in vitro data showing its BiTAC-ADC platform can selectively kill breast cancer cells while sparing healthy cells, valida...
Redwood AI Corp.'s AI-powered platforms aim to accelerate chemistry research and development in pharmaceuticals, defense, public safety, and industria...
NanoViricides has obtained approval from the Pillar Committee in the Democratic Republic of Congo to proceed with a Phase II clinical trial of its ora...
Helus Pharma announced its Chief Medical Officer will participate in a fireside chat at the H.C. Wainwright Neuro Perspectives Conference, highlightin...
Onco-Innovations Limited has initiated process development and scale-up activities for ONC010's active ingredient, a key step toward IND-enabling stud...
Quantum BioPharma Ltd. has completed Phase 1 clinical trials for Lucid-MS, a therapy targeting myelin repair in multiple sclerosis, and filed an IND a...
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference on June 17, 2026, providing commercialization updates and ...
GeoVax CEO comments on recent pharmaceutical acquisitions signaling a strategic shift toward vaccine innovation and health security amid rising global...
Quantum BioPharma's lead drug candidate Lucid-MS aims to address mobility loss in multiple sclerosis by targeting nerve damage, while its commercial p...
Helus Pharma's participation at the Jefferies conference underscores its advancement of proprietary NSAs for mental health disorders, with Phase 3 dat...
TransCode Therapeutics has started a Phase 2a clinical trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduc...
NanoViricides announces that its broad-spectrum antiviral NV-387 could be evaluated for the Bundibugyo Ebola outbreak, as no approved vaccines or ther...
SureNano Science Ltd., through its acquisition of GlucaPharm Inc., is advancing GEP-44, a novel GLP-1 peptide for obesity and metabolic disorders, aim...
Oncotelic Therapeutics integrates 28 million scientific abstracts into its PDAOAI platform, signaling a strategic move to capitalize on the growing AI...
Telomir Pharmaceuticals published peer-reviewed data showing Telomir-Zn improved survival and reduced copper burden in a Wilson’s disease model, expan...
Lantern Pharma announced FDA non-objection to protocol amendments for its Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-...
NanoViricides promotes its oral drug candidate NV-387 as a potential pandemic preparedness tool for Ebola and related filoviruses, leveraging a mechan...
Quantum BioPharma announced that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached midpoint enrollmen...
LIXTE Biotechnology Holdings announced first-quarter 2026 results highlighting continued advancement of lead candidate LB-100 and growth of its Liora ...
Dogwood Therapeutics announced first quarter financial results highlighting progress in its non-opioid pain pipeline, including Phase 2b data for Haln...
Innovations in blood-brain barrier penetration, such as Oncotelic's intranasal nose-to-brain system, are poised to transform CNS drug delivery and unl...
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provis...
Three fatalities on the MV Hondius cruise ship due to hantavirus highlight the dangers of this little-known infection and underscore the need for diag...
NanoViricides received FDA Orphan Drug Designation for its broad-spectrum antiviral NV-387 to treat measles, offering incentives and supporting develo...
VolitionRx announced a technical milestone in detecting nucleosomes from capillary blood using a lateral flow finger-prick prototype, enabling early s...
Helus Pharma announced a collaboration with TARA Mind and VETS to enhance recruitment for its Phase 3 PARADIGM trial targeting major depressive disord...
Ventripoint Diagnostics announced that its strategic partner Lishman Global has submitted the VMS+ 4.0 AI-powered cardiac imaging system to China's NM...
Formycon AG will announce its 2025 financial results on April 22, 2026, and its management will attend several international investor conferences in Q...
Helus Pharma announced the appointment of Dr. Ken Kramer as senior vice president of medical affairs, bringing over two decades of neuroscience medica...
GeoVax announced it will initiate a pivotal Phase 3 trial for its GEO-MVA mpox/smallpox vaccine in the second half of 2026, addressing global vaccine ...
Kairos Pharma's recognition underscores its pioneering work in overcoming cancer drug resistance, with lead candidate ENV-105 targeting CD105 to resto...
HeartBeam (NASDAQ: BEAT) has launched an underwritten public offering to raise capital for advancing its FDA-cleared 12-lead synthesized ECG system, e...
Lixte Biotechnology is advancing its lead candidate LB-100, a first-in-class therapy to enhance existing cancer treatments, and has expanded clinical ...
Lixte Biotechnology is progressing its lead candidate LB-100, a first-in-class therapy that enhances existing cancer treatments, through expanded clin...
NanoViricides announced a Phase II trial for its antiviral NV-387 against MPox in the DR Congo, potentially addressing a public health emergency with ...
